Search
NewLimit is using epigenetic reprogramming to bring cells back to a younger and healthier state, thus tackling age related disease
Co-Founder & President Jacob Kimmel describes the science behind how this works, and the enormous amount of work that goes into choosing which transcription factors to target. The company is currently in IND enabling studies.
23 hours ago
NewLimit raised a $130M series B round last week to advance its work using epigenetic reprogramming to improve cell function and thus aim to extend longevity
Co-Founder & President Jacob Kimmel and Head of Operations Cathy O'Hare describe the scientific approach and how it benefits from the...
May 12, 2025
.png){kind=logo}
